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Abstract
Percutaneous thermal ablation is an emerging treatment option for many tumors of the abdomen not amenable to conventional treatments.
During a thermal ablation procedure, a thin applicator is guided into the target tumor under imaging guidance. Energy is then applied to the tissue
until temperatures rise to cytotoxic levels (50-60 °C). Various energy sources are available to heat biological tissues, including radiofrequency
(RF) electrical current, microwaves, laser light and ultrasonic waves. Of these, RF and microwave ablation are most commonly used worldwide.
During RF ablation, alternating electrical current (~500 kHz) produces resistive heating around the interstitial electrode. Skin surface electrodes
(ground pads) are used to complete the electrical circuit. RF ablation has been in use for nearly 20 years, with good results for local tumor
control, extended survival and low complication rates1,2. Recent studies suggest RF ablation may be a first-line treatment option for small
hepatocellular carcinoma and renal-cell carcinoma3-5. However, RF heating is hampered by local blood flow and high electrical impedance tissues
(eg, lung, bone, desiccated or charred tissue)6,7. Microwaves may alleviate some of these problems by producing faster, volumetric heating8-10. To
create larger or conformal ablations, multiple microwave antennas can be used simultaneously while RF electrodes require sequential operation,
which limits their efficiency. Early experiences with microwave systems suggest efficacy and safety similar to, or better than RF devices11-13
.
Alternatively, cryoablation freezes the target tissues to lethal levels (-20 to -40 °C). Percutaneous cryoablation has been shown to be effective
against RCC and many metastatic tumors, particularly colorectal cancer, in the liver14-16. Cryoablation may also be associated with less
post-procedure pain and faster recovery for some indications17. Cryoablation is often contraindicated for primary liver cancer due to underlying
coagulopathy and associated bleeding risks frequently seen in cirrhotic patients. In addition, sudden release of tumor cellular contents when the
frozen tissue thaws can lead to a potentially serious condition known as cryoshock 16.
Thermal tumor ablation can be performed at open surgery, laparoscopy or using a percutaneous approach. When performed percutaneously, the
ablation procedure relies on imaging for diagnosis, planning, applicator guidance, treatment monitoring and follow-up. Ultrasound is the most
popular modality for guidance and treatment monitoring worldwide, but computed tomography (CT) and magnetic resonance imaging (MRI) are
commonly used as well. Contrast-enhanced CT or MRI are typically employed for diagnosis and follow-up imaging.
Protocol
1. Introduction/Case Presentation:
Example case: 50 yr old female with retroperitoneal leiomyosarcoma s/p primary resection. Had evidence of metastatic disease in the liver and
lung that responded to chemotherapy. Had a single chemo-refractory hepatic lesion. Multidisciplinary discussion led to ablation as a possible
treatment option, given the patient's young age, lack of comorbidities and paucity of alternative chemotherapeutic treatment options. The lesion
was biopsied prior to treatment to confirm metastatic disease. Planning ultrasound demonstrated the lesion in the inferior and posterior aspect of
the left hepatic lobe. Given its proximity to pancreas and bowel, the need for hydrodissection was reviewed with the patient at the time of
consultation.
2. Patient selection
3. Pre-treatment planning
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1. One of the most important aspects of the procedure is to ensure that the patient is an appropriate candidate. This involves a multi-factorial
assessment of both tumor and patient related factors including:
1. Tumor type, size, location and focality (Figure 1).
2. Patient co-morbidities and overall health.
2. Patients should be discussed at a multi-disciplinary tumor board to determine the available treatment alternatives and choose the most
efficacious and appropriate option.
3. The most appropriate ablation modality is variable and dependent on many different factors as well, such as: location of the tumor within the
organ, proximity of adjacent structures and the associated need for precision, experience of the operator, presence of underlying liver disease
or bleeding diatheses. All of these factors and more must be considered to determine and choose the most appropriate ablation modality.
4. Patient must be well informed regarding the procedure, expected risks, possibility of a complete treatment, and likely benefits. Therefore, we
consult with every patient prior to the procedure, usually at the time of planning ultrasound as below.
5. An overall assessment of the patient and procedure will determine the degree of sedation/anesthesia that is both safe and efficacious for the
case.4. Ablation procedure
5. Outcome:
The procedure was successfully carried out using a combination of ultrasound guidance with CT and ultrasound monitoring. A direct injection of
5% dextrose in water (D5W) was used for hydrodissection (Fig. 2). Ultrasound was utilized for guidance since the tumor was easily visualized by
ultrasound imaging but not with non-contrast CT (as is often the case with liver lesions). In our experience, placing applicators with ultrasound
guidance is faster than with CT. Ultrasound does not use ionizing radiation and is therefore safe for both the patient and personnel, and gives
real-time feedback of the tumor and applicator location allowing accurate and consistent placement. Since accurate targeting is so critical to the
success of the procedure, applicator guidance often determines whether or not the procedure will result in a complete treatment.
A combination of ultrasound and CT monitoring was utilized. Ultrasound allows real-time evaluation of the developing ablation while CT gives a
global overview of applicator placement and proximity to adjacent structures, allowing superior assessment of the safety of the applicator
placement and the likelihood of collateral damage to nearby structures. Thus, the combination of ultrasound and CT imaging results in a safer
treatment.
D5W was utilized for hydrodissection for two main reasons: it acts as both a physical and electrical barrier to heating and, therefore, prevents
damage to adjacent structures (i.e. pancreas and bowel), and intraperitoneal D5W has been shown to decrease post-procedural pain in patients
undergoing liver tumor RF ablation. Thus, this intervention makes the procedure both safer and more comfortable for the patient. Follow up
imaging shows that the procedure resulted in a complete treatment of the tumor with no associated complications and there was only minimal
patient discomfort.
Liver tumor ablation is applied most commonly to hepatocellular carcinoma in cirrhotic patients, and in limited hepatic metastatic disease in
patients with colon, breast or neuroendocrine tumors. Patients with other tumor types who have hepatic metastatic disease often have systemic
disease and may not benefit from ablation; these patients are considered on a case-by-case basis. There is a relative paucity of long-term data in
patients with metastatic sarcoma. The decision to proceed with ablation in this case was made given that all the other sites of disease in this
young patient responded to chemotherapy with a single refractory hepatic lesion. Although this may control her disease in the short term and give
her a reprieve from chemotherapy, with a tumor of this type, cure is unlikely. The patient later developed an additional liver lesion and two
pulmonary nodules. All were treated with ablation. The patient is currently under continued surveillance.
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1. We perform a pre-ablation planning ultrasound to determine optimal patient positioning and approach.This also helps us determine whether
or not other imaging modalities will be required for guidance and more notably, monitoring. It is often helpful to have CT available at the time
of the ablation procedure for an overview evaluation of the target tumor, ablation zone, and adjacent structures.
2. We also assess the need for adjuvant techniques at this time with an emphasis on safety and efficacy (Figure 2).
3. During this time we determine the number of applicators likely to be needed to complete the treatment as well as their optimal placement.
1. Patient preparation
1. Factors to be considered/evaluated include: bowel preparation, pre/periprocedural antibiotics, renal/liver function, IV access, need for
an arterial line for blood pressure monitoring, etc. These determinations are made on a case-by-case basis, but there are some general
principles that can be followed and these will be discussed.
2. General anesthesia is common, but ablation can often be performed with deep sedation, or even conscious sedation in some
scenarios. Should be optimized to the individual patient.
2. Equipment setup (note that many aspects of the setup are vendor dependent)
1. Will show an example of RF, cryoablation, and MW ablation equipment and setup including ground pad placement, connections and
testing. For this case, radiofrequency ablation will be utilized.
3. The ablation session
1. Guidance
1. Accurate and appropriate image-guided applicator placement is critical. Since this often includes multiple applicator placements,
particularly for larger tumors, there are many factors to be considered and there are several 'tricks' that can be employed (Figure
3).
2. Adjuvant techniques
1. When performing percutaneous ablation, there are often adjacent structures that may be vulnerable to thermal damage. This has
led to the development of hydrodissection and other displacement techniques, which allow physical, thermal, and electrical
protection when applied appropriately. We will review the use of these techniques.
2. We will also discuss other treatments/techniques that have been shown to, or theoretically can increase efficacy and safety of the
treatment.
3. Monitoring
1. US, CT, and MRI all have specific strengths and weaknesses regarding their ability to effectively and precisely monitor the
growing ablation zone. Because of this, we often utilize a multi-modality approach with both US and CT. This allows us to perform
the procedure safely and effectively.
2. Post-ablation assessment
1. The post-ablation assessment allows the determination of the efficacy of the therapy. When and how it is performed is
variable and will depend on availability of resources, practicality of administering US or CT contrast, and uncertainty
regarding the technical success of the treatment (Figure 4). At our institution, we perform a contrast-enhanced CT on
suitable patients immediately after the ablation session has been concluded. This allows us assess for complete treatment
(with immediate re-treatment while the patient is still under anesthesia if necessary), establish a post procedure baseline
and identify any early complications. However, many institutions perform the initial assessment a month or more after the
ablation session.
4. Follow-up
1. The interval and optimal modality for follow up evaluation varies depending on tumor type and patient factors. We will discuss various
factors that influence this decision and describe an accepted protocol (Figure 5).6. Representative Results:
Figure 1. Pre-procedure CT demonstrating a low attenuation lesion in the left hepatic lobe (arrow) abutting the pancreas (P) with duodenum
located just inferior and stomach just lateral.
Figure 2. Planning ultrasound with the patient in the supine position demonstrates a hypoechoic lesion (arrow) closely abutting the adjacent
stomach (star) and pancreas (not visible). Therefore, a decision was made to place an NG tube for decompression during the procedure and use
hydrodissection to protect the posterior structures.
Figure 3. Ultrasound image (left) demonstrates hydrodissection needle (arrow) extending through the left hepatic lobe in to the space between
the liver and the pancreas with infusion of fluid. Abdominal CT (right) shows the needle in place (arrow) with accumulation of fluid between the
liver and pancreas (P) with posterior displacement of the stomach (star).
Figure 4. Ultrasound image obtained during ablation demonstrates the gas cloud in the lateral left lobe (arrow). A thin layer of fluid can be
observed between the liver and the pancreas (P).
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follow-up CT (right, arrow).
Discussion
Thermal tumor ablation is a safe and effective treatment for many abdominal tumors that are refractory to surgery, or have failed treatment with
radiotherapy/chemotherapy. In addition, it is fast becoming an accepted first-line therapy for some patients. The benefits include: an exceptional
safety profile, a more rapid convalescence than traditional surgical therapies, decreased costs, and excellent local control rates in appropriately
triaged patients. Percutaneous procedures are generally feasible, especially when using techniques such as hydrodissection to improve safety
and targeting of the tumor, thus limiting the morbidity even further. This technique has been utilized in practice for several decades now and many
of the questions regarding long-term outcomes and oncological efficacy are being answered with encouraging results. Thermal ablation will
certainly play an important and growing role in the management of oncology patients over the coming years.
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